This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laugwitz, K.-L. Articles by Schömig, A. Search for Related Content PubMed PubMed Citation Articles by Laugwitz, K.-L. Articles by Schömig, A. Related Collections Contractile function Genomics Heart failure - basic studies

(Circulation. 1999;99:925-933.)
© 1999 American Heart Association, Inc.

Basic Science Reports

Adenoviral Gene Transfer of the Human V2 Vasopressin Receptor Improves Contractile Force of Rat Cardiomyocytes

Karl-Ludwig Laugwitz, MD¹; Martin Ungerer, MD¹; Torsten Schöneberg, MD; Hans-Jörg Weig, MD; Kai Kronsbein, BS; Alessandra Moretti, PhD; Katrin Hoffmann, MS; Melchior Seyfarth, MD; Günter Schultz, MD; Albert Schömig, MD

From I. Medizinische Klinik, Klinikum rechts der Isar, and Deutsches Herzzentrum München, Germany; and Institut für Pharmakologie (T.S., G.S.), Freie Universität Berlin, Germany.

Correspondence to Karl-Ludwig Laugwitz, MD, I. Medizinische Klinik, Klinikum rechts der Isar, Ismaninger Straße 22, D-81675 München, Germany. E-mail laugwitz{at}med1.med.tu-muenchen.de

Background—In congestive heart failure, high systemic levels of the hormone arginine vasopressin (AVP) result in vasoconstriction and reduced cardiac contractility. These effects are mediated by the V1 vasopressin receptor (V1R) coupled to phospholipase C ß-isoforms. The V2 vasopressin receptor (V2R), which promotes activation of the Gs/adenylyl cyclase system, is physiologically expressed in the kidney but not in the myocardium. Expression of a recombinant V2R (rV2R) in the myocardium could result in a positive inotropic effect via the endogenous high concentrations of AVP in heart failure.

Methods and Results—A recombinant adenovirus encoding the human V2R (Ad-V2R) was tested for its ability to modulate the cardiac Gs/adenylyl cyclase system and to potentiate contractile force in rat ventricular cardiomyocytes and in H9c2 cardiomyoblasts. Ad-V2R infection resulted in a virus concentration-dependent expression of the transgene and led to a marked increase in cAMP formation in rV2R-expressing cardiomyocytes after exposure to AVP. Single-cell shortening measurements showed a significant agonist-induced contraction amplitude enhancement, which was blocked by the V2R antagonist, SR 121463A. Pretreatment of Ad-V2R-infected cardiomyocytes with AVP led to desensitization of the rV2R after short-term agonist exposure but did not lead to further loss of receptor function or density after long-term agonist incubation, thus demonstrating resistance of the rV2R to downregulation.

Conclusions—Adenoviral gene transfer of the V2R in cardiomyocytes can modulate the endogenous adenylyl cyclase-signal transduction cascade and can potentiate contraction amplitude in cardiomyocytes. Heterologous expression of cAMP-forming receptors in the myocardium could lead to novel strategies in congestive heart failure by bypassing the desensitized ß-adrenergic receptor signaling.

Key Words: receptors • myocardial contraction • heart failure

This article has been cited by other articles:

				J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]

				J. Gutkowska, M. Miszkurka, B. Danalache, N. Gassanov, D. Wang, and M. Jankowski Functional arginine vasopressin system in early heart maturation Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2262 - H2270. [Abstract] [Full Text] [PDF]

				A. Moretti, H.-J. Weig, T. Ott, M. Seyfarth, H.-P. Holthoff, D. Grewe, A. Gillitzer, L. Bott-Flugel, A. Schomig, M. Ungerer, et al. Essential myosin light chain as a target for caspase-3 in failing myocardium PNAS, September 3, 2002; 99(18): 11860 - 11865. [Abstract] [Full Text] [PDF]

				J. Bonatti, C. Haeusler, A. Klaus, M. Fink, A. Hammerer-Lercher, and G. Laufer Acceptance of gene therapy by the heart surgery patient Eur. J. Cardiothorac. Surg., June 1, 2002; 21(6): 981 - 986. [Abstract] [Full Text] [PDF]

				H.-J. Weig, K.-L. Laugwitz, A. Moretti, K. Kronsbein, C. Stadele, S. Bruning, M. Seyfarth, T. Brill, A. Schomig, and M. Ungerer Enhanced Cardiac Contractility After Gene Transfer of V2 Vasopressin Receptors In Vivo by Ultrasound-Guided Injection or Transcoronary Delivery Circulation, April 4, 2000; 101(13): 1578 - 1585. [Abstract] [Full Text] [PDF]

				U. Klein, C. Muller, P. Chu, M. Birnbaumer, and M. von Zastrow Heterologous Inhibition of G Protein-coupled Receptor Endocytosis Mediated by Receptor-specific Trafficking of beta -Arrestins J. Biol. Chem., May 11, 2001; 276(20): 17442 - 17447. [Abstract] [Full Text] [PDF]

				K.-L. Laugwitz, H.-J. Weig, A. Moretti, E. Hoffmann, P. Ueblacker, I. Pragst, K. Rosport, A. Schomig, and M. Ungerer Gene Transfer of Heterologous G Protein-Coupled Receptors to Cardiomyocytes : Differential Effects on Contractility Circ. Res., April 13, 2001; 88(7): 688 - 695. [Abstract] [Full Text] [PDF]